Biocardia Stock Today
| BCDA Stock | USD 2.60 0.03 1.17% |
PerformanceModest
| Odds Of DistressHigh
|
Biocardia is trading at 2.60 as of the 16th of March 2025, a 1.17 percent increase since the beginning of the trading day. The stock's open price was 2.57. Biocardia has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of March 2008 | Category Healthcare | Classification Health Care |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. The company has 4.58 M outstanding shares of which 56.22 K shares are currently shorted by private and institutional investors with about 0.45 trading days to cover. More on Biocardia
Moving against Biocardia Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Biocardia Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Peter Altman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBiocardia can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biocardia's financial leverage. It provides some insight into what part of Biocardia's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biocardia (BCDA) is traded on NASDAQ Exchange in USA. It is located in 320 Soquel Way, Sunnyvale, CA, United States, 94085 and employs 16 people. Biocardia is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.92 M. Biocardia conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.58 M outstanding shares of which 56.22 K shares are currently shorted by private and institutional investors with about 0.45 trading days to cover.
Biocardia currently holds about 8.61 M in cash with (9.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49.
Check Biocardia Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Biocardia is $11.92 Million. Biocardia retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Biocardia Ownership Details
Biocardia Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 61.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 15.0 | |
| Northern Trust Investments N A | 2024-12-31 | 0.0 | |
| Susquehanna International Group, Llp | 2024-12-31 | 43.8 K | |
| Geode Capital Management, Llc | 2024-12-31 | 31 K | |
| Cm Management, Llc | 2024-12-31 | 25 K | |
| Vanguard Group Inc | 2024-12-31 | 12.9 K | |
| Ubs Group Ag | 2024-12-31 | 4.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 4 K | |
| Pingora Partners Llc | 2024-12-31 | 1 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 899 |
Biocardia Historical Income Statement
Biocardia Stock Against Markets
Biocardia Corporate Management
| Edward Gillis | Senior Devices | Profile | |
| Ian McNiece | Chief Officer | Profile | |
| Sujith Shetty | Chief Regulatory | Profile | |
| Sujith MBBS | Chief Regulatory | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth (0.93) | Return On Assets | Return On Equity |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.